BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Macedo N, Miller DM, Haq R, Kaufman HL. Clinical landscape of oncolytic virus research in 2020. J Immunother Cancer 2020;8:e001486. [PMID: 33046622 DOI: 10.1136/jitc-2020-001486] [Cited by in Crossref: 85] [Cited by in F6Publishing: 92] [Article Influence: 42.5] [Reference Citation Analysis]
Number Citing Articles
1 Li X, Lu M, Yuan M, Ye J, Zhang W, Xu L, Wu X, Hui B, Yang Y, Wei B, Guo C, Wei M, Dong J, Wu X, Gu Y. CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy. OncoImmunology 2022;11:2118210. [DOI: 10.1080/2162402x.2022.2118210] [Reference Citation Analysis]
2 Li S, Sun Z. Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead. Cancer Letters 2022;550:215937. [DOI: 10.1016/j.canlet.2022.215937] [Reference Citation Analysis]
3 Huang C, Dong T, Phung AT, Shah JR, Larson C, Sanchez AB, Blair SL, Oronsky B, Trogler WC, Reid T, Kummel AC. Full Remission of CAR-Deficient Tumors by DOTAP-Folate Liposome Encapsulation of Adenovirus. ACS Biomater Sci Eng 2022. [DOI: 10.1021/acsbiomaterials.2c00966] [Reference Citation Analysis]
4 Wei M, Zuo S, Chen Z, Qian P, Zhang Y, Kong L, Gao H, Wei J, Dong J. Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1017574] [Reference Citation Analysis]
5 Zhang Y, Gabere M, Tylor MA, Simoes CC, Dumbauld C, Barro O, Tesfay MZ, Graham AL, Ferdous KU, Savenka AV, Chamcheu JC, Washam CL, Alkam D, Gies A, Byrum SD, Conti M, Post SR, Kelly T, Borad MJ, Cannon MJ, Basnakian A, Nagalo BM. Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1042250] [Reference Citation Analysis]
6 Huang L, Wang W, Wang Z, Zhang H, Liu H, Wu G, Nie W, Xie H. Engineering Oncolytic Adenoviruses with VSVG‐Decorated Tumor Cell Membranes for Synergistically Enhanced Antitumor Therapy. Adv Funct Materials 2022. [DOI: 10.1002/adfm.202209056] [Reference Citation Analysis]
7 Kong D, Yang Z, Li G, Wu Q, Gu Z, Wan D, Zhang Q, Zhang X, Cheng S, Liu B, Zhang K, Zhang W. SIRPα antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment. BMC Med 2022;20:376. [PMID: 36310169 DOI: 10.1186/s12916-022-02574-z] [Reference Citation Analysis]
8 Gautam S, Xin D, Garcia AP, Spiesschaert B. Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP. Front Bioeng Biotechnol 2022;10. [DOI: 10.3389/fbioe.2022.992069] [Reference Citation Analysis]
9 Jafari M, Kadkhodazadeh M, Shapourabadi MB, Goradel NH, Shokrgozar MA, Arashkia A, Abdoli S, Sharifzadeh Z. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses. Front Immunol 2022;13:1012806. [DOI: 10.3389/fimmu.2022.1012806] [Reference Citation Analysis]
10 Zhu Z, McGray AJR, Jiang W, Lu B, Kalinski P, Guo ZS. Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. Mol Cancer 2022;21:196. [PMID: 36221123 DOI: 10.1186/s12943-022-01664-z] [Reference Citation Analysis]
11 Liu C, Yang M, Zhang D, Chen M, Zhu D. Clinical cancer immunotherapy: Current progress and prospects. Front Immunol 2022;13:961805. [DOI: 10.3389/fimmu.2022.961805] [Reference Citation Analysis]
12 Mulcrone PL, Herzog RW, Xiao W. Adding recombinant AAVs to the cancer therapeutics mix. Mol Ther Oncolytics 2022;27:73-88. [PMID: 36321134 DOI: 10.1016/j.omto.2022.09.009] [Reference Citation Analysis]
13 Phan TA, Tian JP. Hopf bifurcation without parameters in deterministic and stochastic modeling of cancer virotherapy, part I. Journal of Mathematical Analysis and Applications 2022;514:126278. [DOI: 10.1016/j.jmaa.2022.126278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Tang WW, Bauer KM, Barba C, Ekiz HA, O’connell RM. miR-aculous new avenues for cancer immunotherapy. Front Immunol 2022;13:929677. [DOI: 10.3389/fimmu.2022.929677] [Reference Citation Analysis]
15 Wang H, Shi F, Zheng S, Zhao M, Pan Z, Xiong L, Zheng L. Feasibility of hepatocellular carcinoma treatment based on the tumor microenvironment. Front Oncol 2022;12:896662. [DOI: 10.3389/fonc.2022.896662] [Reference Citation Analysis]
16 Mishra AK, Ali A, Dutta S, Banday S, Malonia SK. Emerging Trends in Immunotherapy for Cancer. Diseases 2022;10:60. [DOI: 10.3390/diseases10030060] [Reference Citation Analysis]
17 Yun C, Hong J, Yoon A. Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements. Front Immunol 2022;13:953410. [DOI: 10.3389/fimmu.2022.953410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Konig S, Strobel H, Grunert M, Lyszkiewicz M, Brühl O, Karpel-Massler G, Ziętara N, La Ferla-Brühl K, Siegelin MD, Debatin KM, Westhoff MA. Unblinding the watchmaker: cancer treatment and drug design in the face of evolutionary pressure. Expert Opin Drug Discov 2022. [PMID: 35997138 DOI: 10.1080/17460441.2022.2114454] [Reference Citation Analysis]
19 Asija S, Chatterjee A, Yadav S, Chekuri G, Karulkar A, Jaiswal AK, Goda JS, Purwar R. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds. Int Rev Immunol 2022;:1-24. [PMID: 35938932 DOI: 10.1080/08830185.2022.2101647] [Reference Citation Analysis]
20 Kedarinath K, Fox CR, Crowgey E, Mazar J, Phelan P, Westmoreland TJ, Alexander KA, Parks GD. CD24 Expression Dampens the Basal Antiviral State in Human Neuroblastoma Cells and Enhances Permissivity to Zika Virus Infection. Viruses 2022;14:1735. [PMID: 36016357 DOI: 10.3390/v14081735] [Reference Citation Analysis]
21 Harryvan TJ, Golo M, Dam N, Schoonderwoerd MJA, Farshadi EA, Hornsveld M, Hoeben RC, Hawinkels LJAC, Kemp V. Gastrointestinal cancer-associated fibroblasts expressing Junctional Adhesion Molecule-A are amenable to infection by oncolytic reovirus. Cancer Gene Ther. [DOI: 10.1038/s41417-022-00507-9] [Reference Citation Analysis]
22 Ren Y, Miao J, Wang Y, Fan Z, Kong X, Yang L, Cheng G. Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option. Front Immunol 2022;13:961796. [DOI: 10.3389/fimmu.2022.961796] [Reference Citation Analysis]
23 Lauer UM, Beil J. Oncolytic viruses: challenges and considerations in an evolving clinical landscape. Future Oncol 2022. [PMID: 35818970 DOI: 10.2217/fon-2022-0440] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Groeneveldt C, Kinderman P, van Stigt Thans JJC, Labrie C, Griffioen L, Sluijter M, van den Wollenberg DJM, Hoeben RC, den Haan JMM, van der Burg SH, van Hall T, van Montfoort N. Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy. J Immunother Cancer 2022;10:e004464. [PMID: 35853671 DOI: 10.1136/jitc-2021-004464] [Reference Citation Analysis]
25 Howard F, Conner J, Danson S, Muthana M. Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability. Front Mol Biosci 2022;9:889395. [DOI: 10.3389/fmolb.2022.889395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Giurini EF, Madonna MB, Zloza A, Gupta KH. Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression. Cancers (Basel) 2022;14:2923. [PMID: 35740589 DOI: 10.3390/cancers14122923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Sanborn RE, Schneiders FL, Senan S, Gadgeel SM. Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer. Am Soc Clin Oncol Educ Book 2022;42:1-14. [PMID: 35671433 DOI: 10.1200/EDBK_350967] [Reference Citation Analysis]
28 Engeland CE, Heidbuechel JP, Araujo RP, Jenner AL. Improving immunovirotherapies: the intersection of mathematical modelling and experiments. ImmunoInformatics 2022;6:100011. [DOI: 10.1016/j.immuno.2022.100011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Wang L, Chard Dunmall LS, Cheng Z, Wang Y. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment. J Immunother Cancer 2022;10:e004167. [PMID: 35640930 DOI: 10.1136/jitc-2021-004167] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Mishra AK, Singh SK, Dayanandan S, Banerjee S, Chakraborty S, Gopal AB, Samal S, Poirah I, Chakraborty D, Bhattacharyya A. Hypoxia-driven metabolic heterogeneity and immune evasive behaviour of gastrointestinal cancers: Elements of a recipe for disaster. Cytokine 2022;156:155917. [PMID: 35660715 DOI: 10.1016/j.cyto.2022.155917] [Reference Citation Analysis]
31 de la Nava D, Selvi KM, Alonso MM. Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality. Front Immunol 2022;13:866892. [PMID: 35493490 DOI: 10.3389/fimmu.2022.866892] [Reference Citation Analysis]
32 Jiang X, Wang J, Zheng X, Liu Z, Zhang X, Li Y, Wilhelm J, Cao J, Huang G, Zhang J, Sumer B, Lea J, Lu Z, Gao J, Luo M. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy. J Immunother Cancer 2022;10:e003960. [PMID: 35623658 DOI: 10.1136/jitc-2021-003960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Cerqueira OLD, Antunes F, Assis NG, Cardoso EC, Clavijo-salomón MA, Domingues AC, Tessarollo NG, Strauss BE. Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma. Front Mol Biosci 2022;9:777775. [DOI: 10.3389/fmolb.2022.777775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Bhatt DK, Janzen T, Daemen T, Weissing FJ. Modelling the spatial dynamics of oncolytic virotherapy in the presence of virus-resistant tumor cells.. [DOI: 10.1101/2022.04.06.487254] [Reference Citation Analysis]
35 Feola S, Chiaro J, Martins B, Russo S, Fusciello M, Ylösmäki E, Bonini C, Ruggiero E, Hamdan F, Feodoroff M, Antignani G, Viitala T, Pesonen S, Grönholm M, Branca RMM, Lehtiö J, Cerullo V. A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines. Elife 2022;11:e71156. [PMID: 35314027 DOI: 10.7554/eLife.71156] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Chaudhary H, D'Angelo S. Role of Virus-Directed Therapy in Soft Tissue Sarcoma. Curr Treat Options Oncol 2022. [PMID: 35258792 DOI: 10.1007/s11864-022-00956-2] [Reference Citation Analysis]
37 Zhang Y, Gabere M, Taylor M, Simoes CC, Dumbauld C, Barro O, Chamcheu JC, Post SR, Kelly TJ, Borad MJ, Cannon MJ, Basnakian A, Nagalo BM. Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy.. [DOI: 10.1101/2022.02.25.481685] [Reference Citation Analysis]
38 Yuan F, Wang Y, Ma C. Current WHO Guidelines and the Critical Role of Genetic Parameters in the Classification of Glioma: Opportunities for Immunotherapy. Curr Treat Options Oncol 2022. [PMID: 35182297 DOI: 10.1007/s11864-021-00930-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 White LG, Goy HE, Rose AJ, McLellan AD. Controlling Cell Trafficking: Addressing Failures in CAR T and NK Cell Therapy of Solid Tumours. Cancers (Basel) 2022;14:978. [PMID: 35205725 DOI: 10.3390/cancers14040978] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
40 Ban W, Guan J, Huang H, He Z, Sun M, Liu F, Sun J. Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy. Nano Res . [DOI: 10.1007/s12274-021-4031-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
41 Volovat S, Ursulescu CL, Moisii LG, Volovat C, Boboc D, Scripcariu D, Amurariti F, Stefanescu C, Stolniceanu CR, Agop M, Lungulescu C, Volovat CC. The Landscape of Nanovectors for Modulation in Cancer Immunotherapy. Pharmaceutics 2022;14:397. [DOI: 10.3390/pharmaceutics14020397] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
42 Sonzogni O, Zak DE, Sasso MS, Lear R, Muntzer A, Zonca M, West K, Champion BR, Rottman JB. T-SIGn tumor reengineering therapy and CAR T cells synergize in combination therapy to clear human lung tumor xenografts and lung metastases in NSG mice. OncoImmunology 2022;11:2029070. [DOI: 10.1080/2162402x.2022.2029070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Makuku R, Seyedmirzaei H, Tantuoyir MM, Rodríguez-Román E, Albahash A, Mohamed K, Moyo E, Ahmed AO, Razi S, Rezaei N. Exploring the application of immunotherapy against HIV infection in the setting of malignancy: A detailed review article. Int Immunopharmacol 2022;105:108580. [PMID: 35121225 DOI: 10.1016/j.intimp.2022.108580] [Reference Citation Analysis]
44 Das R, Langou S, Le TT, Prasad P, Lin F, Nguyen TD. Electrical Stimulation for Immune Modulation in Cancer Treatments. Front Bioeng Biotechnol 2021;9:795300. [PMID: 35087799 DOI: 10.3389/fbioe.2021.795300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
45 Abu Khalaf S, Dandachi D, Granwehr BP, Rodriguez-Barradas MC. Cancer immunotherapy in adult patients with HIV. J Investig Med 2022:jim-2021-002205. [PMID: 35086858 DOI: 10.1136/jim-2021-002205] [Reference Citation Analysis]
46 Cristi F, Gutiérrez T, Hitt MM, Shmulevitz M. Genetic Modifications That Expand Oncolytic Virus Potency. Front Mol Biosci 2022;9:831091. [DOI: 10.3389/fmolb.2022.831091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
47 Carter ME, Koch A, Lauer UM, Hartkopf AD. Clinical Trials of Oncolytic Viruses in Breast Cancer. Front Oncol 2021;11:803050. [PMID: 35004328 DOI: 10.3389/fonc.2021.803050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Hernandez-aguirre I, Cassady KA. Oncolytic viruses in immunotherapy. Cancer Immunology and Immunotherapy 2022. [DOI: 10.1016/b978-0-12-823397-9.00012-0] [Reference Citation Analysis]
49 Di Trani CA, Cirella A, Arrizabalaga L, Fernandez-sendin M, Bella A, Aranda F, Melero I, Berraondo P. Overcoming the limitations of cytokines to improve cancer therapy. International Review of Cell and Molecular Biology 2022. [DOI: 10.1016/bs.ircmb.2022.05.002] [Reference Citation Analysis]
50 Yajima S, Sugawara K, Iwai M, Tanaka M, Seto Y, Todo T. Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma. Mol Ther Oncolytics 2021;23:402-11. [PMID: 34853811 DOI: 10.1016/j.omto.2021.10.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
51 Bhatt DK, Wekema L, Carvalho Barros LR, Chammas R, Daemen T. A systematic analysis on the clinical safety and efficacy of onco-virotherapy. Mol Ther Oncolytics 2021;23:239-53. [PMID: 34761104 DOI: 10.1016/j.omto.2021.09.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
52 Yang L, Gu X, Yu J, Ge S, Fan X. Oncolytic Virotherapy: From Bench to Bedside. Front Cell Dev Biol 2021;9:790150. [PMID: 34901031 DOI: 10.3389/fcell.2021.790150] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
53 Bots ST, Kemp V, Cramer SJ, van den Wollenberg DJ, Hornsveld M, Lamfers M, van der Pluijm G, Hoeben RC. Non-human primate adenoviruses of the Human Adenovirus B species are potent and broadly-acting oncolytic vector candidates. Hum Gene Ther 2021. [PMID: 34861769 DOI: 10.1089/hum.2021.216] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Liu H, Qiu W, Sun T, Wang L, Du C, Hu Y, Liu W, Feng F, Chen Y, Sun H. Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds. Acta Pharmaceutica Sinica B 2022;12:1781-804. [DOI: 10.1016/j.apsb.2021.12.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
55 Alvarez M, Molina C, De Andrea CE, Fernandez-Sendin M, Villalba M, Gonzalez-Gomariz J, Ochoa MC, Teijeira A, Glez-Vaz J, Aranda F, Sanmamed MF, Rodriguez-Ruiz ME, Fan X, Shen WH, Berraondo P, Quintero M, Melero I. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. J Immunother Cancer 2021;9:e002953. [PMID: 34824158 DOI: 10.1136/jitc-2021-002953] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
56 Xie Y, Xie F, Zhang L, Zhou X, Huang J, Wang F, Jin J, Zhang L, Zeng L, Zhou F. Targeted Anti-Tumor Immunotherapy Using Tumor Infiltrating Cells. Adv Sci (Weinh) 2021;8:e2101672. [PMID: 34658167 DOI: 10.1002/advs.202101672] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
57 Rahman MM, McFadden G. Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy. Cancers (Basel) 2021;13:5452. [PMID: 34771615 DOI: 10.3390/cancers13215452] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
58 Humeau J, Le Naour J, Galluzzi L, Kroemer G, Pol JG. Trial watch: intratumoral immunotherapy. Oncoimmunology 2021;10:1984677. [PMID: 34676147 DOI: 10.1080/2162402X.2021.1984677] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
59 Santos Apolonio J, Lima de Souza Gonçalves V, Cordeiro Santos ML, Silva Luz M, Silva Souza JV, Rocha Pinheiro SL, de Souza WR, Sande Loureiro M, de Melo FF. Oncolytic virus therapy in cancer: A current review. World J Virol 2021; 10(5): 229-255 [PMID: 34631474 DOI: 10.5501/wjv.v10.i5.229] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
60 Jin S, Wang Q, Wu H, Pang D, Xu S. Oncolytic viruses for triple negative breast cancer and beyond. Biomark Res 2021;9:71. [PMID: 34563270 DOI: 10.1186/s40364-021-00318-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
61 Xie R, Bi X, Shang B, Zhou A, Shi H, Shou J. Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis. Virol J 2021;18:158. [PMID: 34332591 DOI: 10.1186/s12985-021-01630-z] [Reference Citation Analysis]
62 Marchini A, Ilkow CS, Melcher A. Oncolytic Virus Immunotherapy. Cancers (Basel) 2021;13:3672. [PMID: 34359574 DOI: 10.3390/cancers13153672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Nettelbeck DM, Leber MF, Altomonte J, Angelova A, Beil J, Berchtold S, Delic M, Eberle J, Ehrhardt A, Engeland CE, Fechner H, Geletneky K, Goepfert K, Holm PS, Kochanek S, Kreppel F, Krutzke L, Kühnel F, Lang KS, Marchini A, Moehler M, Mühlebach MD, Naumann U, Nawroth R, Nüesch J, Rommelaere J, Lauer UM, Ungerechts G. Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies. Viruses 2021;13:1420. [PMID: 34452286 DOI: 10.3390/v13081420] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
64 Jahedi S, Wang L, Watmough J. Fighting cancer with oncolytic viral therapy: identifying threshold parameters for success.. [DOI: 10.1101/2021.07.19.452846] [Reference Citation Analysis]
65 Mokhtari RB, Sambi M, Qorri B, Baluch N, Ashayeri N, Kumar S, Cheng HM, Yeger H, Das B, Szewczuk MR. The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. Cancers (Basel) 2021;13:3596. [PMID: 34298809 DOI: 10.3390/cancers13143596] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
66 Shi H, Li K, Ni Y, Liang X, Zhao X. Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. Front Cell Dev Biol 2021;9:707198. [PMID: 34336860 DOI: 10.3389/fcell.2021.707198] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
67 Spiesschaert B, Angerer K, Park J, Wollmann G. Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits. Cancers (Basel) 2021;13:3386. [PMID: 34298601 DOI: 10.3390/cancers13143386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
68 Malogolovkin A, Gasanov N, Egorov A, Weener M, Ivanov R, Karabelsky A. Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes. Viruses 2021;13:1271. [PMID: 34209981 DOI: 10.3390/v13071271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
69 Ma XY, Hill BD, Hoang T, Wen F. Virus-inspired strategies for cancer therapy. Semin Cancer Biol 2021:S1044-579X(21)00191-7. [PMID: 34182141 DOI: 10.1016/j.semcancer.2021.06.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
70 Varudkar N, Oyer JL, Copik A, Parks GD. Oncolytic parainfluenza virus combines with NK cells to mediate killing of infected and non-infected lung cancer cells within 3D spheroids: role of type I and type III interferon signaling. J Immunother Cancer 2021;9:e002373. [PMID: 34172515 DOI: 10.1136/jitc-2021-002373] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
71 Liu W, Liu Y, Hu C, Xu C, Chen J, Chen Y, Cai J, Yan G, Zhu W. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells. Int J Cancer 2021;149:1369-84. [PMID: 34086978 DOI: 10.1002/ijc.33703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Guo ZS. Oncolytic Virus Immunotherapy: Showcasing Impressive Progress in Special Issue II. Biomedicines 2021;9:663. [PMID: 34200560 DOI: 10.3390/biomedicines9060663] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
73 Feola S, Chiaro J, Martins B, Russo S, Fusciello M, Ylösmäki E, Hamdan F, Feodoroff M, Antignani G, Viitala T, Pesonen S, Grönholm M, Branca RMM, Lehtiö J, Cerullo V. A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.. [DOI: 10.1101/2021.06.08.447483] [Reference Citation Analysis]
74 Monie DD, Correia C, Zhang C, Ung CY, Vile RG, Li H. Modular network mechanism of CCN1-associated resistance to HSV-1-derived oncolytic immunovirotherapies for glioblastomas. Sci Rep 2021;11:11198. [PMID: 34045642 DOI: 10.1038/s41598-021-90718-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Gray SG. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma. BMC Pulm Med 2021;21:148. [PMID: 33952230 DOI: 10.1186/s12890-021-01513-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
76 Chizenga EP, Abrahamse H. Biological Therapy with Complementary and Alternative Medicine in Innocuous Integrative Oncology: A Case of Cervical Cancer. Pharmaceutics 2021;13:626. [PMID: 33924844 DOI: 10.3390/pharmaceutics13050626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Abd-Aziz N, Poh CL. Development of oncolytic viruses for cancer therapy. Transl Res 2021:S1931-5244(21)00104-3. [PMID: 33905949 DOI: 10.1016/j.trsl.2021.04.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
78 Geisler A, Hazini A, Heimann L, Kurreck J, Fechner H. Coxsackievirus B3-Its Potential as an Oncolytic Virus. Viruses 2021;13:718. [PMID: 33919076 DOI: 10.3390/v13050718] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
79 Heidbuechel JPW, Engeland CE. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. J Hematol Oncol 2021;14:63. [PMID: 33863363 DOI: 10.1186/s13045-021-01075-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 19.0] [Reference Citation Analysis]
80 Floyd W, Pierpoint M, Su C, Luo L, Deland K, Wisdom AJ, Zhu D, Ma Y, Dewitt SB, Williams NT, Somarelli JA, Corcoran DL, Eward WC, Cardona DM, Kirsch DG. Atrx deletion impairs cGAS-STING signaling and increases response to radiation and oncolytic herpesvirus in sarcoma.. [DOI: 10.1101/2021.03.08.434225] [Reference Citation Analysis]
81 Kaufman HL. Can Surgeons Expand the Role of Oncolytic Viruses for Cancer Treatment? An Editorial Comment on "Fighting Fire with Fire: Oncolytic Virotherapy in Thoracic Malignancies". Ann Surg Oncol 2021;28:2432-3. [PMID: 33475883 DOI: 10.1245/s10434-020-09491-6] [Reference Citation Analysis]
82 Vannini A, Leoni V, Sanapo M, Gianni T, Giordani G, Gatta V, Barboni C, Zaghini A, Campadelli-Fiume G. Immunotherapeutic Efficacy of Retargeted oHSVs Designed for Propagation in an Ad Hoc Cell Line. Cancers (Basel) 2021;13:E266. [PMID: 33445744 DOI: 10.3390/cancers13020266] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
83 Zhang Q, Wu W, Zhang J, Xia X. Merits of the 'good' viruses: the potential of virus-based therapeutics. Expert Opin Biol Ther 2021;21:731-40. [PMID: 33322950 DOI: 10.1080/14712598.2021.1865304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
84 Athanasiadis P, Ravikumar B, Carragher NO, Clemons PA, Johanssen T, Ebner D, Aittokallio T. Optimized chemogenomic library design strategies for precision oncology.. [DOI: 10.1101/2020.11.30.403329] [Reference Citation Analysis]
85 Olagnier D, Alain T. Oncolytic viral immunotherapy in the time of COVID-19. Cytokine Growth Factor Rev 2020;56:1-3. [PMID: 33183956 DOI: 10.1016/j.cytogfr.2020.10.009] [Reference Citation Analysis]
86 Menotti L, Avitabile E. Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.Int J Mol Sci. 2020;21. [PMID: 33167582 DOI: 10.3390/ijms21218310] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]